Mounjaro
Tirzepatide · Once weekly
Acts at GIP and GLP-1 receptors involved in appetite and blood-glucose regulation.
Can be injected with or without food.
Read the complete guidePut up to four medicines side by side. See the evidence, day-to-day differences and current first-order price references — with the caveats kept in view.
These are separate categories, not interchangeable UK weight-management options. Read each authorisation and evidence note.
It describes a particular study group at a particular time. It does not tell you how much weight you will lose, or which medicine will suit you. Compare selected medicines to open the full records.
Tirzepatide · Once weekly
Acts at GIP and GLP-1 receptors involved in appetite and blood-glucose regulation.
Can be injected with or without food.
Read the complete guideSemaglutide · Once weekly
A GLP-1 receptor agonist that affects appetite regulation and glucose-dependent insulin secretion.
Can be injected with or without food.
Read the complete guideSemaglutide · Once daily
Oral semaglutide acts at GLP-1 receptors. Its formulation enables absorption, which depends on the administration conditions.
Take whole after at least eight hours fasting with no more than 120 mL water, then wait at least 30 minutes before food, drink or other oral medicines.
Read the complete guideOrforglipron · Once daily
A small-molecule, non-peptide GLP-1 receptor agonist. It is a different active ingredient from tirzepatide.
Can be taken at any time, without food or water restrictions; swallow the tablet intact.
Read the complete guideThe comparator includes SURMOUNT-1, STEP 1, STEP UP, OASIS 4, ATTAIN-1 and SURMOUNT-5. It keeps each study’s population, duration, dose and estimand attached to the reported result. An estimand describes the treatment effect a trial is trying to measure, including how treatment discontinuation is handled.
SURMOUNT-5 is a direct comparison of maximum tolerated tirzepatide 10 or 15 mg and semaglutide 1.7 or 2.4 mg injections. Its findings do not compare tirzepatide with Wegovy 7.2 mg, Wegovy tablets or Foundayo. Separate placebo-controlled trials cannot establish a league table between those medicines.
There are no interpolated Mounjaro results for 7.5 or 12.5 mg, and no invented Foundayo result for 14.5 mg. ATTAIN-1 used research capsules; where the UK product information establishes a tablet equivalent, that distinction is shown. A research dose is not an instruction for your prescription.
A marketing authorisation, NHS funding recommendation, local eligibility and pharmacy stock are different things. Research-only entries are labelled. Rybelsus is shown as a diabetes medicine, not as another name for Wegovy tablets. Qsymia’s presence is not a claim that it is authorised in the UK.
Evidence checked 2026-11-20. AI-assisted source review; independent clinical review is pending. Price methodology · Editorial policy.